Introduction {#S0001}
============

Radiofrequency ablation (RFA) is a treatment method that utilizes radiofrequency alternating current to ablate tissue around the needle electrode. Over the last 10 years, this technique has been gaining popularity in several fields of oncological surgery \[[@CIT0001]--[@CIT0003]\]. The introduction of RFA into other fields of surgery has fuelled the interest to study its application in treatment of small renal masses (SRM), less than 4 cm. Some controversies remain, however, regarding its oncological efficacy. The RFA is a minimally invasive therapeutic modality for renal tumours. It can be an alternative to nephrectomy in patients with single kidney, bilateral tumours, von Hippel-Lindau disease and in those with contraindications for surgery \[[@CIT0004]--[@CIT0006]\]. The aim of this paper is to present our experiences with application of RFA in patients who could be qualified for nephron-sparing surgery (NSS) due to T1a kidney tumours.

Material and methods {#S0002}
====================

Twenty-three patients out of 129 who underwent RFA in the years 2003-2010 were retrospectively analysed. The inclusion criteria were age below 70 years, lack of major comorbidities (ASA score 1 or 2), and competent contralateral kidney ([Table I](#T0001){ref-type="table"}). Tumours were qualified based on computed tomography (CT) and all were staged as T1a (average size 2.6 ±0.5 cm). Pre-treatment biopsy was performed. Ultrasound-guided RFA was performed using alternating current (460 kHz) conducted directly to the tumour with a needle electrode. Patients were followed according to guidelines prepared for NSS.

###### 

Patients undergoing radiofrequency ablation (RFA) due to small renal masses

  No.   Age \[years\]   ASA score   Initial creatinine \[µmol/l\]   Tumour size \[cm\]   Pre-treatment biopsy   Re-treatment      Final histology   Followup \[months\]
  ----- --------------- ----------- ------------------------------- -------------------- ---------------------- ----------------- ----------------- ---------------------
  1     60              2           84                              2.0                  Indefinite                                                 70
  2     56              2           61                              2.8                  Indefinite                                                 54
  3     56              2           65                              2.0                  cRCC                   Radical surgery   cRCC              52
  4     50              1           99                              2.5                  Indefinite                                                 50
  5     46              2           80                              2.7                  Not assessed                                               43
  6     52              2           45                              3.4                  Indefinite                                                 40
  7     60              1           88                              2.9                  Indefinite                                                 39
  8     60              2           53                              2.5                  cRCC                                                       35
  9     60              2           72                              4.0                  Indefinite                                                 29
  10    58              2           60                              2.4                  cRCC                                                       28
  11    37              1           57                              2.0                  cRCC                   NSS               Necrosis          26
  12    52              2           71                              2.5                  cRCC                                                       17
  13    50              2           70                              1.0                  cRCC                                                       16
  14    64              2           62                              2.6                  cRCC                   RFA                                 16
  15    62              2           67                              3.0                  Not assessed           RFA                                 15
  16    63              2           71                              3.0                  Indefinite             RFA                                 14
  17    68              2           77                              1.8                  Indefinite             NSS               Oncocytoma        13
  18    70              2           81                              1.5                  Indefinite                                                 11
  19    64              2           70                              3.4                  cRCC                                                       11
  20    62              2           62                              4.0                  cRCC                                                       6
  21    55              2           74                              2.5                  Not assessed                                               6
  22    58              1           84                              3.0                  Cancer cells                                               6
  23    47              2           43                              2.3                  Indefinite                                                 5

cRCC -- clear cell type renal carcinoma, NSS -- nephron-sparing surgery

Results {#S0003}
=======

In 20 of 23 patients the tumour was successfully biopsied before RFA and 10 of these biopsies were positive and revealed cancer. Six patients required additional treatment due to recurrence visible in CT -- 3 with a positive biopsy result, 1 with negative and 2 without biopsy. Three of them were treated with a second session of RFA, 1 with radical nephrectomy and 2 with partial nephrectomy ([Table I](#T0001){ref-type="table"}). No disease dissemination was observed and all patients who received additional treatment due to recurrence remain disease free. Average follow-up time was 2 years (5 months to 5.8 years).

Discussion {#S0004}
==========

While RFA allows ablative success to be achieved, it requires acceptance of re-treatment necessity in a certain percentage of cases. Although the recurrence risk after RFA is higher in comparison to radical nephrectomy, early detection with an appropriate follow-up often allows successful treatment with an additional RFA session or partial nephrectomy. In certain cases radical nephrectomy is required. Most of the patients retain their kidney and remain disease free. In our experience, the recurrence risk did not influence the survival or progression rate.

It must also be stressed that RFA is a minimally invasive treatment which can even be performed under local anaesthesia and is connected with shorter hospital stay than NSS or even laparoscopic nephrectomy. Complications after RFA are less frequent and they are more often minor in comparison to surgical series \[[@CIT0004], [@CIT0007]\]. These facts render RFA an attractive minimally invasive treatment for SRM, which can be offered instead of partial nephrectomy \[[@CIT0004]\]. The study cohort was small because of specific inclusion criteria -- such patients should, according to guidelines, undergo NSS, while RFA is mainly recommended for older ones with serious comorbidities.

An important issue to be resolved is an informative and appropriately performed renal tumour biopsy (RTB). The RTBs gained popularity in the evaluation of SRM because imaging alone is insufficient to assess the underlying tumour aggressiveness. The complication rate was low, and neoplasm seeding along the needle track has been reported to be extremely rare \[[@CIT0008]\]. A certain disadvantage of RTB is a considerable, although improving over time, percentage of 'indefinite' biopsy results. The RTB is recommended to help differentiating benign from malignant SRM prior or during ablative therapies and in follow-up, especially after RFA \[[@CIT0006]--[@CIT0008]\].

The RFA was planned based on computed tomography examination prior to treatment while the procedure itself was performed under USG guidance. Effectiveness of US-guided RFA is reported to be comparable with CT-guided RFA results \[[@CIT0009]\]. The RFA is safe and effective in renal tumours; corticomedullary lesions and tumours \> 3 cm, however, are associated with an increased probability of incomplete ablation. In tumours \> 5 cm, RFA has a significant failure rate \[[@CIT0007]\]. The RFA provided successful treatment of SRM with a low recurrence rate as well as prolonged metastasis-free and cancer-specific survival rates at 5 years after treatment \[[@CIT0005]\].

Conclusions {#S0005}
===========

It seems that RFA can be safely performed in selected patients with T1a tumour as an alternative to partial nephrectomy. The tumour should be biopsied prior to RFA. Careful follow-up, similar to the one after NSS, is required after thermal ablation and allows early detection and successful treatment of recurrences.
